Jazz Pharmaceuticals' (JAZZ) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a research note released on Wednesday,Benzinga reports. The firm currently has a $210.00 price objective on the specialty pharmaceutical company's stock.

JAZZ has been the topic of several other research reports. Barclays reiterated an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Royal Bank of Canada lowered their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $189.40.

Remove Ads

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $2.36 during trading hours on Wednesday, reaching $138.81. The company's stock had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06. The company's 50-day moving average is $128.14 and its 200-day moving average is $120.03. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $8.43 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 25,193 shares of company stock worth $3,533,122 over the last quarter. Corporate insiders own 4.20% of the company's stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently bought and sold shares of JAZZ. Stephens Inc. AR raised its stake in Jazz Pharmaceuticals by 16.1% during the third quarter. Stephens Inc. AR now owns 5,563 shares of the specialty pharmaceutical company's stock worth $620,000 after buying an additional 771 shares during the last quarter. Van ECK Associates Corp increased its stake in Jazz Pharmaceuticals by 11.4% in the third quarter. Van ECK Associates Corp now owns 60,211 shares of the specialty pharmaceutical company's stock valued at $6,691,000 after purchasing an additional 6,157 shares in the last quarter. Philip James Wealth Mangement LLC bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $830,000. CWA Asset Management Group LLC bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $3,197,000. Finally, Crossmark Global Holdings Inc. increased its stake in Jazz Pharmaceuticals by 23.6% in the third quarter. Crossmark Global Holdings Inc. now owns 5,083 shares of the specialty pharmaceutical company's stock valued at $567,000 after purchasing an additional 970 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.